Analysts called a recent stock sell-off at Embecta (Nasdaq:EMBC) “unwarranted” and believe the company is moving in the right direction despite recent challenges. Late last year, Embecta filed with the state of Massachusetts to confirm a workforce reduction affecting 118 employees. This related to the company’s plans to discontinue its insulin patch pump program and restructure. […]
Wall Street Beat
Dexcom expects sales to grow 14% in 2025
Dexcom (Nasdaq:DXCM) today announced preliminary financial results with projections for significant sales growth in 2025. Shares of DXCM dipped 1.5% to $76.57 in mid-morning trading today. The San Diego-based continuous glucose monitor (CGM) maker reported preliminary 2024 revenues of $4.032 billion. That marks an 11% increase over 2023. For 2025, Dexcom anticipates total revenue of […]
Senseonics to consider reverse stock split, reports strong Eversense 365 interest
Senseonics (NYSE:SENS) announced preliminary financial results for 2024 as it considers a reverse stock split. Given a recent appreciation in the company’s share price, Senseonics decided not to proceed with a planned special meeting of stockholders. The company took this decision to consider the stock split. Shares of SENS rose 43% to 62¢ apiece at […]
Beta Bionics is proposing an IPO
Beta Bionics announced today that it filed a registration statement with the SEC relating to a proposed initial public offering (IPO). The amount of shares of common stock included in the IPO and the price range remain undetermined. Irvine, California-based Beta Bionics filed to list its common stock on the Nasdaq market under the “BBNX” […]
Embecta discontinues insulin patch pump program, plans restructuring
Embecta (Nasdaq:EMBC) announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan. Shares of EMBC ticked up 4.3% to $14.41 apiece before hours after the company announced the discontinuation as part of its fourth-quarter earnings results. The BD Diabetes spinoff won FDA approval for a disposable patch pump system […]
Senseonics reports mixed Q3 results, positive Eversense 365 outlook
Senseonics (NYSE:SENS) shares dipped slightly before hours today on third-quarter results that came in mixed compared to the consensus forecast. Shares of SENS fell 2.5% to 34¢ apiece in pre-market trading today. The Germantown, Maryland-based implantable continuous glucose monitor (CGM) maker reported losses of $23.98 million. That equals 4¢ per share on sales of $4.26 […]
Insulet stock rises on Q3 beat, raised sales guidance
Insulet (Nasdaq:PODD) shares ticked up today on third-quarter results that came in well ahead of the consensus forecast. Shares of PODD rose 3.3% to $257 apiece in post-market trading today. The Acton, Massachusetts-based automated insulin delivery system maker reported profits of $77.5 million. That equals $1.08 per share on sales of $543.9 million for the […]
Tandem stock rises on 31% Q3 sales growth, raised guidance
Tandem Diabetes Care (Nasdaq:TNDM) shares ticked up after hours today on third-quarter results that topped the consensus forecast. Shares of TNDM rose 5% to $35.85 apiece in post-market trading today. The San Diego-based automated insulin delivery system maker reported losses of $23.3 million. That equals 35¢ per share on sales of nearly $244 million for […]
Phillips Medisize to buy inhaled drug delivery device maker Vectura from Philip Morris
Phillips Medisize parent company Molex announced that it agreed to acquire Vectura from a subsidiary of cigarette maker Philip Morris. Vectura designs and develops devices and formulations for inhaled drug delivery. Philip Morris paid $1.2 billion for the UK-based company in 2021 as part of its “Beyond Nicotine” effort to phase out cigarettes and develop […]
The 9 largest diabetes technology companies in the world
Diabetes technology comes in all shapes and sizes: insulin delivery systems, continuous glucose monitors and more. The companies that develop these technologies come in all shapes and sizes, too. Some focus entirely (or almost entirely) on solutions for people with diabetes. Others are much larger medtech firms that still have sizable business units that focus […]
